Bevacizumab for front-Line Treatment of Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer Patients With High Risk of Relapse: a Cost Effective option for Canadian Patients

Saved in:
Bibliographic Details
Published inValue in health Vol. 18; no. 3; p. A202
Main Authors Ghatage, P, Wright, E.J, Martin Nunez, I, Yin, L, Ray, J
Format Journal Article
LanguageEnglish
Published 01.05.2015
Subjects
Internal Medicine
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
DOI:10.1016/j.jval.2015.03.1168